Related Experiment Video
Updated: Jul 11, 2026
Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
Published on: June 16, 2020
Estimating the burden of scleroderma disease in Spain
Ana Villaverde-Hueso1, Elena Sánchez-Valle, Elena Alvarez
1Instituto de Investigacion de Enfermedades Raras, Instituto de Salud Carlos III, Sinesio Delgado 6-8, Madrid, Spain.
Objective:
Scleroderma (systemic sclerosis) is a rare disease that results in great suffering. We estimated the burden of disease posed by scleroderma and its relative importance in the health of the Spanish population.
Methods:
We estimated scleroderma-based burden of disease following procedures developed for the Global Burden of Disease study to ensure comparability.
Results:
Despite its low prevalence, scleroderma generated 1732 disability-adjusted life-years (DALY) in Spain in 2001, comprising 562 (32%) years of life lost and 1170 (68%) years lived with disability. Most scleroderma-related DALY (73%) occurred in the population aged 15-54 years. Estimated DALY accounted for 0.59% of other musculoskeletal disorder-related DALY in the European A subregion (countries with low mortality rate in both adults and children in the World Health Organization classification), a significant value in the overall burden of disease.
Conclusion:
The burden of scleroderma in Spain was high, with disability being the major contributing factor. Burden of disease is an important measure in rare diseases, and may be an important indicator to be considered as a health unit in developed countries.
